Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Articles|February 7, 2011
Quiz on Violent Behavior, Anxiety in Children, Delusions
Is violent behavior a proxy indicator for the relationship between severity of substance abuse and suicide risk? What has the strongest influence in promoting doubt about a delusion in a patient with schizophrenia? These questions and more.
Advertisement
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Don't miss out on these CME articles! Test your knowledge here.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
5